Despite a dip in product sales, PTN progresses in clinical developments and maintains a stable financial footing.
Q3 2024 Palatin Technologies Inc Earnings Call
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2024.